Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trinity Biotech PLC TRIB

Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.


NDAQ:TRIB - Post by User

Post by MarketFalcon87on Nov 30, 2024 12:23pm
30 Views
Post# 36338992

Earnings Show No Big Surprises for $TRIP—What's Next?

Earnings Show No Big Surprises for $TRIP—What's Next?So, the latest earnings from $TRIP didn’t really move the needle. The company’s still profitable, but it’s nothing to write home about—slight revenue growth, but not enough to justify the stock price popping back to pre-pandemic levels. The market’s clearly been less than enthusiastic. But you know what? That might be the time to buy, especially if you’re a contrarian. If you can stomach the volatility, this stock could be a nice value play in 2025. That said, I’m also watching $BOLT closely. People are talking about it making a big move soon, so I’ve got my eye on that one too. Anyone else holding $TRIP, or are you waiting for something more exciting to jump in?
<< Previous
Bullboard Posts